Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | PRCP | P42785 | 11/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853975 | 0.90 | HPGDS (0.43) | HPGDSPRCPSSTR3PRMT5 | |
| SCHEMBL13145752 | 0.90 | HPGDS (0.43) | HPGDSPRCPSSTR3PRMT5 | |
| SCHEMBL825074 | 0.82 | HPGDS (0.50) | HPGDSPRCPSSTR3GPR119 | |
| SCHEMBL19701047 | 0.81 | PRCP (0.37) | HPGDSPRCPSSTR3PRMT5GPR119 | |
| SCHEMBL20484405 | 0.81 | PRCP (0.37) | HPGDSPRCPSSTR3PRMT5GPR119 | |
| SCHEMBL855900 | 0.81 | HTR2C (0.40) | PRCP | |
| SCHEMBL825064 | 0.81 | HTR2C (0.40) | PRCP | |
| SCHEMBL17563565 | 0.81 | HPGDS (0.46) | HPGDSPRCPSSTR3 | |
| SCHEMBL12159995 | 0.81 | HPGDS (0.46) | HPGDSPRCPSSTR3 | |
| SCHEMBL13635812 | 0.81 | HPGDS (0.46) | HPGDSPRCPSSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HPGDS 582/4885PRCP 190/4885SSTR3 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.